Cipla recalls 5.8 lakh packets of gastric ulcer treatment drug from US market–business today

Clipped from: https://www.businesstoday.in/current/corporate/cipla-recalls-58-lakh-packets-of-gastric-ulcer-treatment-drug-from-us-market/story/427526.html

The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary

Cipla recalls 5.8 lakh packets of gastric ulcer treatment drug from US market

The USFDA cited “cross-contamination with other products” as the reason for the company recalling the product

Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market, the latest Enforcement Report by the USFDA said.

The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary. The USFDA cited “cross-contamination with other products” as the reason for the company recalling the product. “The excipient, Crospovidone, NF is contaminated with theophylline,” it added.

As per the US regulator, the company is recalling 2,84,610 packets of 10 mg strength and 2,89,350 packets of 20 mg strength. Further, it is also recalling 6,491 packets of esomeprazole magnesium for delayed-release oral suspension in 40 mg strength. The company has initiated the countrywide recall December 17, 2020, and the USFDA has classified it as a Class II recall.

As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. In a separate statement, the USFDA said Strides Pharma Inc, a subsidiary of Bengaluru-based Strides Pharma Science, is recalling 960 bottles of Tacrolimus capsules (100mg) due to “failed moisture limits”.

The company has initiated the countrywide recall of the affected lot on December 22, 2020. The USFDA has classified it as a Class III recall, which is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s